Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation (ASCT) for Hodgkin lymphoma (HL).

8043 Background: ASCT is the standard of care for patients with relapsed HL. Most relapses occur in the first 2 years (y) after ASCT and the long term outcomes for 2 y post-ASCT survivors have not been well described. No prospective trials have compared the impact of different conditioning regimens on outcomes. Methods: We searched the Nebraska Lymphoma Study Group database to identify patients with HL who received ASCT from 1984 to 2007. Patients were conditioned with CBV (cyclophosphamide 6000 mg/m2, BCNU 300 mg/m2 and etoposide 600-900 mg/m2) or BEAM (BCNU 300 mg/m2, etoposide 800 mg/m2, cytarabine 800 mg/m2 and melphalan 140 mg/m2). Progression, progression-free survival (PFS) and overall survival (OS) were compared between the 2 regimens while adjusting for significant patient, disease and transplant related characteristics. Results: The median duration of follow up was 8 (2-26) y. Among the 461 transplanted patients, during the study period, 330 received CBV and 131 received BEAM. At 2 y post-ASCT, ...